Archived AES Symposia 2004
Epileptogenesis and the Progressive Nature of the Disease
Program Length: 1 hrs 58 min
Epileptogenesis is generally understood to be the process by which a seizure focus develops. However, it can also represent the evolution of excitatory processes or worsening of seizures over time. This symposium will discuss whether there is evidence for ongoing epileptogenesis after the onset of a seizure diathesis. In addition, the evidence for the progressive nature of epilepsy, specifically as shown by MRI studies and changes in neuropsychiatric status, will be discussed. Finally, a careful discussion of whether AEDs alter the course of epilepsy will be presented, with an eye toward how that information may affect treatment of patients with refractory epilepsy. The faculty will be composed of speakers known for their experience and knowledge in this area, and chaired by a physician whose credentials include current research related to the topic.
At the conclusion of this activity, participants should be able to:
- Discuss the leading theories of epileptogenesis in epilepsy
- Identify the structural and neuropsychological changes that may occur in patients with refractory epilepsy
- List which patients, based on epidemiology, are more likely to be at risk
- Apply knowledge of the effects of AEDs on the long-term course of the disease to selection of agents appropriate for patients.
Epileptologists, neurologists, general practitioners, internists, and RNs who treat patients with epilepsy.
Chair: Jacqueline A. French, M.D.
- Evidence for Progressive Structural and Neuropsychological Abnormalities in Epilepsy
Kimford J. Meador, M.D.
- Clinical Epidemiology of Refractory Epilepsy
W. Allen Hauser, M.D.
- Do AEDs Alter the Course of Epilepsy?
Jacqueline A. French, M.D.
This program and its re-purposing on the AES Web site with CME credit is supported by an educational grant from UCB Pharma, Inc.
Dr. Meador has disclosed the following affiliations with commercial supporters of CME:
Grants/research support: GlaxoSmithKline; Ortho-McNeil Pharmaceutical, Inc.; Pfizer Inc; SAM Technology, Inc; Shire US Inc; and UCB Pharma, Inc
Consultant: Abbott Laboratories; GlaxoSmithKline; Elan Corporation, plc; Lexicor Health System, Inc; NeuroPace, Inc; Novartis Pharmaceuticals Corporation; Ortho-McNeil Pharmaceutical, Inc; Pfizer Inc; Shire US Inc; and UCB Pharma, Inc
Honoraria: GlaxoSmithKline; Ortho-McNeil Pharmaceutical, Inc; Pfizer Inc; Shire US Inc; and UCB Pharma, Inc
Dr Meador has disclosed that he will not be discussing the unlabeled/unapproved use of any products.
Dr Hauser has indicated that he has nothing to disclose.
Dr Hauser has disclosed that he will not be discussing the unlabeled/unapproved use of any product.
Dr French has disclosed the following affiliations with commercial supporters of CME:
Grants/Research support: UCB Pharma, Inc
Consultant: Esai Pharmaceuticals and UCB Pharma, Inc
Dr French has disclosed that she will not be discussing the unlabeled/unapproved use of any product.